Intellectual property policies in early-phase research in public-private partnerships.
Hilde Stevens, Geertrui Van Overwalle, Bart Van Looy, Isabelle Huys
Author Information
- Hilde Stevens: Department of Pharmaceutical and Pharmacological Sciences, Research Centre for Clinical Pharmacology and Pharmacotherapy, University of Leuven, Leuven, Belgium.
- Geertrui Van Overwalle: Centre for IT &IP Law (CiTiP), University of Leuven, Leuven, Belgium.
- Bart Van Looy: Department of Managerial Economics, Strategy and Innovation, University of Leuven, Leuven, Belgium.
- Isabelle Huys: Department of Pharmaceutical and Pharmacological Sciences, Research Centre for Clinical Pharmacology and Pharmacotherapy, University of Leuven, Leuven, Belgium.
No abstract text available.
- Sci Transl Med. 2012 Feb 22;4(122):122cm3
[PMID: 22357536]
- Clin Pharmacol Ther. 2010 May;87(5):521-3
[PMID: 20407454]
- Nat Rev Drug Discov. 2014 Feb;13(2):83-4
[PMID: 24481293]
- Nat Med. 2014 Jun;20(6):564-5
[PMID: 24901552]
- Vaccine. 2007 May 16;25(20):4003-11
[PMID: 17363119]
- Biotechnol Law Rep. 2015 Aug 1;34(4):153-165
[PMID: 26396462]
Drug Industry
Intellectual Property
Models, Organizational
Organizational Policy
Ownership
Private Sector
Public Sector
Public-Private Sector Partnerships
Research
